Compare Gilead Sciences, Inc. (GILD) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Harmony Gold Mining Co. — how do they compare? Gilead Sciences, Inc. trades at $133.52 (market cap $163.51B), while Harmony Gold Mining Co. trades at $14.93 (market cap $9.38B). The key difference: Gilead Sciences, Inc. is far larger — about 17.4× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| GILD | HMY | |
|---|---|---|
Market Cap | $163.51B | $9.38B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $26.04 |
52-Week Low | $108.22 | $12.61 |
Enterprise Value | $178.05B | $9.72B |
Dividend Yield | 2.49% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Harmony Gold Mining (HMY) trades at $15.24, up 1.67% today, with bearish technical signals from moving averages. The company shows strong fundamentals with 2024 revenue of $61.38B and net income of $8.59B, delivering a 20.06% net margin. Recent earnings show mixed results with a Q4 2025 miss but previous quarters beating expectations. The stock offers a dividend yield with a $0.31 payment scheduled for May 2026.
HMY presents value with attractive valuation ratios (P/E 9.69, EV/EBITDA 5.04) and robust profitability (ROE 32.32%). However, analyst sentiment is cautious with 70% hold ratings, and technical indicators suggest near-term pressure. Key risks include gold price volatility and Federal Reserve policy impacts, while the transition to gold-copper hybrid operations offers long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
